# Trinity Innovation Bioventure Singapore

Trinity Innovation Bioventure Singapore is a Venture Capital based in Singapore, Singapore.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Singapore, Singapore
- **Region:** Asia
- **Address:** Singapore
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** www.trinity-fund.com.sg
- **LinkedIn:** https://www.linkedin.com/company/trinity-innovation-bioventure-singapore

## Regulatory record

- **Reports private funds:** No

## About

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund investing in Asia markets. It has made one investment to date. The fund invested in Axcynsis Therapeutics as part of a Seed VC round on May 06, 2022.

## Sectors

- Biotech
- Digital Health
- Healthcare Services

## Questions

### What investment stages does Trinity Innovation Bioventure Singapore target?

Trinity focuses on early-stage investments, specifically seed and start-up rounds. The firm enters at the point where laboratory-validated science requires first institutional capital to fund preclinical development, initial clinical trials, or early commercial pilots. This stage focus aligns with Singapore's translational research pipeline, where grant-funded discoveries at institutions like A*STAR and the National University of Singapore seek venture backing to spin out and scale.

### Which sectors does Trinity Innovation Bioventure Singapore explicitly back?

The firm invests in biotech, medical devices, diagnostics, and digital health platforms. It does not publicly pursue non-healthcare venture themes such as enterprise software, fintech, or consumer internet. The mandate is deliberately narrow — life sciences and healthcare innovation only — reflecting a bet that Asia's disease burden and aging demographics will drive demand for therapeutics and care-delivery technologies developed closer to the region's populations.

### How does Trinity Innovation Bioventure Singapore source its deal flow?

Deal flow originates primarily from Singapore's public-sector biomedical research ecosystem, including institutes under the Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, and the National University of Singapore. The firm also maintains relationships with academic tech-transfer offices and hospital innovation units. This institutional proximity gives Trinity access to science-led spinouts before they are broadly marketed to regional or global venture firms.

## Related profiles

- [Trinity Hunt Partners](https://altss.com/profile/trinity-hunt-partners)
- [Trinity Private Equity Group](https://altss.com/profile/trinity-private-equity-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/trinity-innovation-bioventure-singapore

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology